Use of gene markers to guide antihypertensive therapy

Current Hypertension Reports

Volumn 3, Issue 5, 2001, Pages 410-415

  Turner, Stephen T ^a   Schwartz, Gary L ^a   Chapman, Arlene B ^a   Boerwinkle, Eric ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFECT; FORECASTING; GENETIC MARKER; GENETICS; HUMAN; HYPERTENSION; REVIEW;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; FORECASTING; GENETIC MARKERS; HUMANS; HYPERTENSION;

EID: 0035488869     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-001-0059-x     Document Type: Review

References (50)

1. Burt VL, Whelton P, Roccella E.J., et al.: Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991 [see comments]. Hypertension 1995, 25:305-133.
2. Nelson C, Woodwell D: National Ambulatory Medical Care Survey: 1993 summary. In Vital & Health Statistics - Series 13: Data From the National Health Survey. 1998: iii-vi.
3. Motulsky A: Drug reactions, enzymes and biochemical genetics. JAMA 1957, 165:835-837.
4. Collins FS: Shattuck lecture-medical and societal consequences of the Human Genome Project. N Engl J Med 1999, 341:28-37.
5. Venter JC, Adams MD, Myers E.W., et al.: The sequence of the human genome. Science 2001, 291:1304-1351.
6. Lander ES, Linton LM, Birren B, et al: Initial sequencing and analysis of the human genome. Nature 2001, 409:860-921.
7. Sachidanandam R, Weissman D, Schmidt S.C., et al.: A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001, 409:928-933.
8. Zoccali C, Mallamaci F, Cuzzola F., et al.: Reproducibility of the response to short-term low salt intake in essential hypertension [see comments]. J Hypertens 1996, 14:1455-1459.
9. Chatellier G, Day M, Bobrie G., et al.: Feasibility study of N-of-1 trials with blood pressure self-monitoring in hypertension. Hypertension 1995, 25:294-301.
10. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure]. Arch Intern Med 1997, 157:2413-2446.
11. Published erratum appears in Arch Intern Med 1998, 158: 573.]
12. Turner ST, Schwartz GL, Chapman A.B., et al.: C825T Polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001, 37:739-743.
13. Sumner D, Meredith P, Howie C., et al.: Initial blood pressure as a predictor of the response to antihypertensive therapy. Br J Clin Pharmacol 1988, 26: 715.
14. Materson BJ, Reda DJ, Cushman W.C., et al.: Single-drug therapy for hypertension in men. A comparison of six antihyperten-sive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents [see comments]. N Engl J Med 1993, 328:914-921.
15. Published erratum appears in N Engl J Med 1994, 330: 1689.]
16. Jamerson K, DeQuattro V: The impact of ethnicity on response to antihypertensive therapy. Am J Med 1996, 101: 22S-32S.
17. Seedat Y: Varying responses to hypotensive agents in different racial groups: black versus white differences. J Hypertens 1989, 7:515-518.
18. Preston RA, Materson BJ, Reda D.J., et al.: Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents [see comments]. JAMA 1998, 280:1168-1172.
19. Chapman AB, Schwartz GL, Boerwinkle E, et al: Predictors of antihypertensive response to a standard dose of hydrochlo-rothiazide in African-Americans and Caucasians with essential hypertension. Kidney Int 2001, In press.
20. Miller JZ, Weinberger MH, Christian J.C., et al.: Familial resemblance in the blood pressure response to sodium restriction. Am J Epidemiol 1987, 126:822-830.
21. Weber WW: Pharmacogenetics. New York: Oxford University Press; 1997.
22. Lennard M, Silas J, Freestone S., et al.: Oxidation phenotype-a major determinant of metoprolol metabolism and response. N Engl J Med 1982, 307:1558-1560.
23. Shepherd A, McNay J, Ludden T., et al.: Plasma concentration and acetylator phenotype determine response to oral hydralazine. Hypertension 1981, 3:580-585.
24. Lachman H, Papolos D, Saito T., et al.: Human catechol O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996, 6:243-250.
25. Israili ZH: Correlation of pharmacological effects with plasma levels of antihypertensive drugs in man. Ann Rev Pharmacol Toxicol 1979, 19:25-52.
26. Burnier M, Brunner H: Comparative antihypertensive effects of angiotensin II receptor antagonists. J Am Soc Nephrol 1999, 10: S278-S282.
27. Ekbom T, Lindholm L, Oden A., et al.: A 5-year prospective, observational study of the withdrawal of antihypertensive treatment in elderly people. J Intern Med 1994, 235:581-588.
28. Laragh J, Lamport B, Sealey J., et al.: Diagnosis Ex Juvantibus. Individual response patterns to drugs reveal hypertension mechanisms and simplify treatment. Hypertension 1988, 12:223-226.
29. Gonzalez F, Skoda R, Kimura S., et al.: Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 1988, 331:442-446.
30. Pecker M: Pathophysiologic effects and strategies for longterm diuretic treatment of hypertension. In Hypertension: Pathophysiology, Diagnosis, and Management. Edited by Laragh J, Brenner B. New York: Raven Press, Ltd.; 1990:2143-2167.
31. Lifton R: Molecular genetics of human blood pressure variation. Science 1996, 272:676-680.
32. Lifton RP, Gharavi AG, Geller DS: Molecular mechanisms of human hypertension. Cell 2001, 104:545-556.
33. Bianchi G, Tripodi G, Casari G., et al.: Two point mutations within the adducin gene are involved in blood pressure variation. Proc Natl Acad Sci U S A 1994, 9 1: 3999-4003.
34. Tripodi G, Valtorta F, Torielli L., et al.: Hypertension-association point mutations in the adducin a and B subunits affect actin cytoskeleton and ion transport. J Clin Invest 1996, 97:2815-2822.
35. Manunta P, Barlassin C, Bianchi G: Adducin in essential hypertension. FEBS Lett 1998, 430:41-44.
36. Cusi D, Barlassina C, Azzani T., et al.: Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension [see comments]. Lancet 1997, 349:1353-1357.
37. Published erratum appears in Lancet 1997 350: 524.]
38. Glorioso N, Manunta P, Filigheddu F., et al.: The role of a-adducin polymorphism in blood pressure and sodium handling regulation may not be excluded by a negative association study. Hypertension 1999, 34:649-654.
39. Hunt S, Cook N, Oberman A., et al.: Angiotensinogen genotype, sodium reduction, weight loss, and prevention of hypertension. Trials of hypertension prevention, phase II. Hypertension 1998, 32:393-401.
40. Hunt S, Geleijnse J, Wu L., et al.: Enhanced blood pressure response to mild sodium reduction in subjects with the 235T variant of the angiotensinogen gene. Am J Hypertens 1999, 12:460-466.
41. Hiraga H, Oshima T, Watanabe M., et al.: Angiotensin I-converting enzyme gene polymorphism and salt sensitivity in essential hypertension. Hypertension 1996, 27:569-572.
42. Kojima S, Inenaga T, Matsuoka H., et al.: The association between salt sensitivity of blood pressure and some polymorphic factors. J Hypertens 1994, 12:797-801.
43. O'Donnell C.J., Lindpaintner K, Larson M.G., et al.: Evidence for association and genetic linkage of the angiotensin converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study [see comments]. Circulation 1998, 97:1766-1772.
44. Fornage M, Amos C, Kardia S., et al.: Variation in the region of the angiotensin-converting enzyme gene influences interin-dividual differences in blood pressure levels in young white males. Circulation 1998, 97:1773-1779.
45. Siffert W, Rosskopf D, Siffert G., et al.: Association of a human G-protein B3 subunit variant with hypertension. Nat Genet 1998, 18:5-48.
46. Siffert W, Rosskopf D, Mortiz A., et al.: Enhanced G protein activation in immortalized lymphoblasts from patients with essential hypertension. J Clin Invest 1995, 96:759-766.
47. Siffert W, Rosskopf D, Erbel R: Genetic polymorphism in the G protein, 3 subunit, obesity, and hypertension. Herz 2000, 25:26-33.
48. Siffert W, Naber C, Walla M., et al.: G protein B3 subunit 825T allele and its potential association with obesity in hypertensive individuals. J Hypertens 1999, 17:1095-1098.
49. Schunkert H, Hense H, Doring A., et al.: Association between a polymorphism in the G protein B3-subunit gene and lower renin and elevated diastolic blood pressure levels. Hypertension 1998, 32:510-513.
50. Vincent M, Samani NJ, Gauguier D, et al: A pharmacogenetic approach to blood pressure in Lyon hypertensive rats. A chromosome 2 locus influences the response to a calcium antagonist. J Clin Invest 1997, 100:2000-2006.